Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 30, Issue 1, 2008, Pages 3-11

  Kishi, Takuya ^a   Hirooka, Yoshitaka ^a   Shimokawa, Hiroaki ^a   Takeshita, Akira ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Brain; Hypertension; Oxidative stress; Statin; Sympathetic nervous system

Indexed keywords

ATORVASTATIN; NORADRENALIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART RATE; HYPERTENSION; MALE; MEDULLA OBLONGATA; MOUSE; NONHUMAN; OXIDATIVE STRESS; STROKE; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; URINARY EXCRETION;

ANIMALS; BLOOD PRESSURE; BRAIN; HEART RATE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDULLA OBLONGATA; NITRIC OXIDE; NOREPINEPHRINE; OXIDATIVE STRESS; PYRROLES; RATS; RATS, INBRED SHR; SYMPATHETIC NERVOUS SYSTEM; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 38549092439     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960701813429     Document Type: Article

References (42)

1. Kerr S, Brosnan J, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension. Hypertension. 1999;33:1353-1358.
2. Nakazono K, Watanabe N, Matsuno K, Sakai J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA. 1991;88:10045-10048.
3. Ohtsuki T, Matsumoto M, Suzuki K, Taniguchi N, Kamada T. Mitochondrial lipid peroxidation and superoxide dismutase in rat hypertensive target organs. Am J Physiol. 1995;268:H1418-H1421.
4. Kimoto-Kinoshita S, Nishida S, Tomura TT. Age-related change of antioxidant capacities in the cerebral cortex and hippocampus of stroke-prone spontaneously hypertensive rats. Neurosci Lett. 1999;273:41-44.
5. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation. 2004;109:2357-2362.
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival study (4S). Lancet. 1994;344:1383-1389.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
8. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trials. Lancet. 2003;361:1149-1158.
9. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
10. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-8885.
11. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450-1457.
12. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation. 1997;95:1126-1131.
13. Mital S, Zhang X, Zhao G, Bernstein RD, Smith CJ, Fulton DL, Sessa WC, Liao JK, Hintze TH. Simvastatin upregulates coronary endothelial nitric oxide production conscious dogs. Am J Physiol. 2000;279:H2649-H2657.
14. Laufs U, LaFata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
15. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.
16. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5:372-378.
17. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Atheroscler Thromb Vasc Biol. 2001;21:3-5.
18. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
19. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
20. Landmesser U, Bahlmann F, Mueller BS, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, De Groot K, Fliser D, Fauler G, Marz W, Drexler H. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-2363.
21. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens. 2003;21:379-386.
22. Hamilton CA, Brosnan MJ, Mclntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging. Hypertension. 2001;37:529-534.
23. Sakai K, Hirooka Y, Matsuo I, Eshima K, Shigematsu H, Shimokawa H, Takeshita A. Overexpression of eNOS in NTS causes hypotension and bradycardia in vivo. Hypertension. 2000;36:1023-1028.
24. Hirooka Y, Sakai K, Kishi T, Takeshita A. Adenovirus-mediated gene transfer into the NTS in conscious rats: a new approach to examining the central control of cardiovascular regulation. Ann NY Acad Sci. 2001;940:197-205.
25. Kishi T, Hirooka Y, Sakai K, Shigematsu H, Shimokawa H, Takeshita A. Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension. 2001;38:896-901.
26. Kishi T, Hirooka Y, Ito K, Sakai K, Shimokawa H, Takeshita A. Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;39:264-268.
27. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press; 1998.
28. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87-96.
29. Thakur NK, Hayashi T, Sumi D, Kano H, Tsunekawa T, Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am J Physiol. 2001;281:H75-H83.
30. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315-2320.
31. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range or initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
32. Haendeler J, Hoffmann J, Zeiher AM, Dimmler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: A novel vasculoprotective function of statins. Circulation. 2004;110:856-861.
33. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003;108:1567-1574.
34. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
35. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113-118.
36. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increase nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002;105:933-938.
37. Kondo M, Terada M, Fujiwara T, Arita N, Yano A, Tabei R. Noradrenergic hyperinnervation in the heart of stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl. 1995;22:S75-S76.
38. Cilla DD, Whitefield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687-695.
39. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005;36:1298-1300.
40. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, Tremoli E. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by anti-inflammatory effects. Arterioscler Thromb Vasc Biol. 2005;25:598-603.
41. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A, De Caterina R. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: An ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001;51:283-293.
42. Landmesser U, Engberding N, Bahlmann F, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Hornig B, Haller H, Drexler H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-1939.